SgI-29 peptide

SgI-29 peptide

• Handling and Storage of Synthetic Peptides
• Material Safety Data Sheets (MSDS)

Batch to batch variation of the purity

HNKQEGRDHDKSKGHFHRVVIHHKGGKAH

His-Asn-Lys-Gln-Glu-Gly-Arg-Asp-His-Asp-Lys-Ser-Lys-Gly-His-Phe-His-Arg-Val-Val-Ile-His-His-Lys-Gly-Gly-Lys-Ala-His

29

97%

Synthetic

Powder

Activity primarily against Gram-negative bacteria such as E. coli ATCC 25922 (MIC 1.67 uM), E. coli ML-35p (MIC 2.2 uM), E. coli clinic strain 1 (1.05 uM), E. coli clinic strain 2 (1.17 uM), Pseudomonas aeruginosa ATCC 27853 (MIC 1.567 uM), P. aeruginosa CMCCB 10104 (MIC 2.17 uM), P. aeruginosa PA 01 (MIC 3.8 uM). SgI-29 showed weaker activity against Gram-positive bacteria such as S. aureus (MIC > 30 uM). SgI-29 has Antimicrobial activity. The source of SgI-29 is human seminal plasma, Homo sapiens.

Normally, this peptide will be delivered in lyophilized form and should be stored in a freezer at or below -20 °C. For more details, please refer to the manual: Handling and Storage of Synthetic Peptides

Trifluoroacetic acid (TFA) is a common counterion from the purification process using High-Performance Liquid Chromatography (HPLC). The presence of TFA can affect the peptide's net weight, appearance, and solubility.

Impact on Net Weight: The TFA salt contributes to the total mass of the product. In most cases, the peptide content constitutes >80% of the total weight, with TFA accounting for the remainder.

Solubility: TFA salts generally enhance the solubility of peptides in aqueous solutions.

In Biological Assays: For most standard in vitro assays, the residual TFA levels do not cause interference. However, for highly sensitive cellular or biochemical studies, please be aware of its presence.